Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Approved for Two China Trials of Multiple Myeloma Treatment

publication date: Oct 14, 2019

Shanghai's I-Mab Biopharma has been approved to conduct China Phase II/III trials of an anti-CD38 antibody in patients with multiple myeloma. The company in-licensed China rights to MOR202/TJ202 two years ago from Germany's MorphoSys in a $120 million agreement. The Phase II/III trials are an extension of MorphoSys' Phase II/III global trials as well as I-Mab's similar trials in Taiwan. I-Mab owns rights for MOR202/TJ202 in China, Taiwan, Hong Kong and Macao. More details....

Stock Symbol: (FSE: MOR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.